An oral HemokineTM, alpha-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivo
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Faller, Douglas V.Castaneda, Serguei A.
Zhou, Daohong
Vedamony, Merriline
Newburger, Peter E.
White, Gary L.
Kosanke, Stanley
Plett, P. Artur
Orschell, Christie M.
Boosalis, Michael S.
Perrine, Susan P.
UMass Chan Affiliations
Department of Pediatrics, Division of Hematology/OncologyDocument Type
Journal ArticlePublication Date
2017-02-28
Metadata
Show full item recordAbstract
An oral therapeutic which reduces duration of cytopenias and is active following accidental radiation exposures is an unmet need in radiation countermeasures. Alpha methylhydrocinnamate (ST7) prolongs STAT-5 phosphorylation, reduces growth-factor dependency of multi-lineage cell lines, and stimulates erythropoiesis. Here, ST7 and its isomers were studied for their effects on myeloid progenitors and hematopoietic stem cells (HSCs) following radiation, in nonhuman primates, and murine irradiation models. Addition of ST7 or ST7-S increased CFU-GM production by 1.7-fold (p<0.001), reduced neutrophil apoptosis comparable to G-CSF, and enhanced HSC survival post-radiation by 2-fold, (p=0.028). ST7 and ST7-S administered in normal baboons increased ANC and platelet counts by 50-400%. In sub-lethally-irradiated mice, ANC nadir remained > 200/mm3 and neutropenia recovered in 6days with ST7 treatment and 18days in controls (p<0.05). In lethally-irradiated mice, marrow pathology at 15days was hypocellular (10% cellularity) in controls, but normal (55-75% cellularity) with complete neutrophil maturation with ST7-S treatment. Following lethal irradiation, ST7, given orally for 4days, reduced mortality, with 30% survival in ST7-animals vs 8% in controls, (p<0.05). Collectively, the studies indicate that ST7 and ST7-S enhance myeloid recovery post-radiation and merit further evaluation to accelerate hematologic recovery in conditions of radiation-related and other marrow hypoplasias.Source
Blood Cells Mol Dis. 2017 Mar;63:1-8. doi: 10.1016/j.bcmd.2016.10.021. Epub 2016 Oct 31. Link to article on publisher's siteDOI
10.1016/j.bcmd.2016.10.021Permanent Link to this Item
http://hdl.handle.net/20.500.14038/43566PubMed ID
27888688Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.bcmd.2016.10.021